← Leaderboards
Michael J Silverberg
Kaiser Foundation Research Institute
$13,556,779
Attributed
$26,411,837
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,061,829 · 11
By mechanism
R01$19,849,468 · 7
U01$5,860,649 · 2
K01$701,720 · 1
U54$649,992 · 1
Top collaborators
- Derek D. Satre21 shared
- Elizabeth Chiao5 shared
- Robert D Dubrow4 shared
- Alan S Go4 shared
- George F Sawaya4 shared
- Chun R. Chao3 shared
- Douglas Allen Corley1 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Chun R. Chao$8,592,282
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyCaringPersonsMortalityBaseHiv InfectionsCohort StudiesMalignant NeoplasmsElectronic Health RecordSamplingAgingPharmaceutical PreparationsRisk FactorsCaliforniaWomanFollow-UpMental DepressionDesignComorbidityHealth SystemRandomized TrialInterviewCancer RiskSample Size
Grant awards (46)
Effectiveness of the HPV Vaccine in Immunocompromised Populations$827,605
R01 · FY2025 · AI · contact PI
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,549
R01 · FY2025 · CA · contact PI
Assessing Syndemics of Cardiovascular Disease in People with and without HIV$780,520
R01 · FY2025 · HL · contact PI
Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation$651,022
R01 · FY2025 · CA
Effectiveness of the HPV Vaccine in Immunocompromised Populations$826,914
R01 · FY2024 · AI · contact PI
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$808,120
R01 · FY2024 · CA · contact PI
Assessing Syndemics of Cardiovascular Disease in People with and without HIV$770,930
R01 · FY2024 · HL · contact PI
Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation$633,588
R01 · FY2024 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,310
R01 · FY2023 · CA · contact PI
Assessing Syndemics of Cardiovascular Disease in People with and without HIV$729,917
R01 · FY2023 · HL · contact PI
Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation$654,794
R01 · FY2023 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$808,055
R01 · FY2022 · CA · contact PI
Assessing Syndemics of Cardiovascular Disease in People with and without HIV$721,966
R01 · FY2022 · HL · contact PI
Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation$713,715
R01 · FY2022 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,377
R01 · FY2021 · CA · contact PI
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA$573,066
U01 · FY2021 · AA · contact PI
HIV Status and Incidence and Outcomes of Heart Failure$624,664
R01 · FY2020 · HL · contact PI
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA$610,414
U01 · FY2020 · AA · contact PI
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$529,032
R01 · FY2020 · DA
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$133,523
R01 · FY2020 · DA
HIV Status and Incidence and Outcomes of Heart Failure$712,672
R01 · FY2019 · HL · contact PI
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA$597,583
U01 · FY2019 · AA · contact PI
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$538,622
R01 · FY2019 · DA
HIV Status and Incidence and Outcomes of Heart Failure$720,906
R01 · FY2018 · HL · contact PI
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$664,390
R01 · FY2018 · DA
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA$592,224
U01 · FY2018 · AA · contact PI
HIV Status and Incidence and Outcomes of Heart Failure$749,492
R01 · FY2017 · HL · contact PI
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$682,826
R01 · FY2017 · DA
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA$607,613
U01 · FY2017 · AA · contact PI
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients, U01AA021997 Admin Supplement$66,338
U01 · FY2017 · AA
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care population$699,854
R01 · FY2016 · DA
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients$501,418
U01 · FY2016 · AA
Antiretroviral Therapy Strategies to Lower Cancer Risk in HIV-Infected Persons$557,051
R01 · FY2015 · CA · contact PI
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients$507,286
U01 · FY2015 · AA
Antiretroviral Therapy Strategies to Lower Cancer Risk in HIV-Infected Persons$709,818
R01 · FY2014 · CA · contact PI
Optimizing Colonscopy & Fecal Immunochemical Tests for Community-Based Screening$649,992
U54 · FY2014 · CA
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients$597,689
U01 · FY2014 · AA
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients$596,508
U01 · FY2013 · AA
Antiretroviral Therapy Strategies to Lower Cancer Risk in HIV-Infected Persons$570,918
R01 · FY2013 · CA · contact PI
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients$610,510
U01 · FY2012 · AA
Antiretroviral Therapy Strategies to Lower Cancer Risk in HIV-Infected Persons$606,318
R01 · FY2012 · CA · contact PI
HIV Infection, Antiretroviral Therapy, Cancer Incidence and Progression$140,344
K01 · FY2011 · AI · contact PI
HIV Infection, Antiretroviral Therapy, Cancer Incidence and Progression$140,344
K01 · FY2010 · AI · contact PI
HIV Infection, Antiretroviral Therapy, Cancer Incidence and Progression$140,344
K01 · FY2009 · AI · contact PI
HIV Infection, Antiretroviral Therapy, Cancer Incidence and Progression$140,344
K01 · FY2008 · AI · contact PI
HIV Infection, Antiretroviral Therapy, Cancer Incidence and Progression$140,344
K01 · FY2007 · AI · contact PI